Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro MedicusPMDIY 77 3-1 Month Momentum % is 6.06% as of Sep. 22, 2026. GuruFocus rates PMDIY with a GF Score™ of 77/100 and a GF Value™ of $31.75 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Pro Medicus ranks better than 73.24% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Pro Medicus's 3-1 Month Momentum % is 6.06%.
The industry rank for Pro Medicus's 3-1 Month Momentum % or its related term are showing as below:
PMDIY's 3-1 Month Momentum % is ranked better than 73.24% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 0.63
vs PMDIY: 6.06
Pro Medicus (OTCPK:PMDIY) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Pro Medicus 3-1 Month Momentum % Related Terms
PMDIY vs VEEV, BTSG, TEM: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, Pro Medicus's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Pro Medicus's 3-1 Month Momentum % falls into.
Pro Medicus (OTCPK:PMDIY) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus (PMDIY) has a 3-1 Month Momentum % of 6.06% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pro Medicus and its competitors. According to the industry distribution chart, Pro Medicus ranks #179 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 26.8%.
Is Pro Medicus' 3-1 Month Momentum % too high?
Pro Medicus' current 3-1 Month Momentum % is 6.06%. The Healthcare Providers & Services industry median 3-1 Month Momentum % is 0.63. Pro Medicus' value of 6.06% is 861.9% above this industry median. Based on the distribution chart, Pro Medicus ranks #179 out of 669 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Pro Medicus has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #179 out of 669 companies for 3-1 Month Momentum %. This puts Pro Medicus in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.63. Pro Medicus' value of 6.06% is 861.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
The median 3-1 Month Momentum % among Healthcare Providers & Services companies is 0.63, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current 3-1 Month Momentum % of 6.06% is 861.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median 3-1 Month Momentum % is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current 3-1 Month Momentum % is 6.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (PMDIY) is currently considered Modestly Undervalued. The stock's GF Value™ is $31.75, compared to a current price of $23.63 — trading 25.6% below its estimated fair value. The current 3-1 Month Momentum % is 6.06% and 861.9% above the Healthcare Providers & Services industry median of 0.63. Pro Medicus' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Pro Medicus (PMDIY), the current 3-1 Month Momentum % is 6.06% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (PMDIY) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of $23.63 is trading 25.6% below its estimated GF Value™ of $31.75.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for PMDIY:
3-1 Month Momentum %: 6.06%
GF Value™: $31.75 vs. price of $23.63 (25.6% below fair value)
Industry Position: 861.9% above the Healthcare Providers & Services median (#179 of 669)
No single metric tells the full story. See the PMDIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
77GF Score
Get the complete analysis for PMDIY
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDIY has been successfully added to your 
